Healthcare - Biotechnology - NASDAQ - US
$ 87.83
-7.63 %
$ 4.75 B
Market Cap
-123.7
P/E
CASH FLOW STATEMENT
208 M
OPERATING CASH FLOW
-155 M
INVESTING CASH FLOW
279 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Arcellx, Inc.
| Net Income | -70.7 M |
| Depreciation & Amortization | 2.04 M |
| Capital Expenditures | -21.4 M |
| Stock-Based Compensation | 41.8 M |
| Change in Working Capital | 225 M |
| Others | 241 M |
| Free Cash Flow | 186 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (70.7) | (188.7) | (65.0) | (32.1) | (18.0) | (8.3) |
| Depreciation & Amortization | 2.0 | 1.3 | 1.0 | 0.6 | 0.3 | 93 K |
| Deferred Income Tax | 0 | 0 | 0 | (3.6) | 100 K | 0 |
| Stock Based Compensation | 41.8 | 21.5 | 6.8 | 1.1 | 0.1 | 66 K |
| Other Operating Activities | 9.0 | 62.1 | 0.2 | 3.6 | 100 K | 0.9 |
| Change in Working Capital | 225.4 | 4.5 | 2.7 | 1.8 | (1.3) | 0.4 |
| Cash From Operations | 207.6 | (99.3) | (54.2) | (28.7) | (18.8) | (6.9) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (21.4) | (2.3) | (5.8) | (0.9) | (3.8) | (0.5) |
| Other Items | (133.1) | (115.4) | (74.2) | 0 | 0 | 0 |
| Cash From Investing Activities | (154.5) | (117.7) | (80.0) | (0.9) | (3.8) | (0.5) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 24 K | 0 | 0 | 0 |
| Total Debt Repaid | (29.4) | (9.7) | (0.4) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 8.8 | 2.5 | 118.9 | 41.7 | 42.7 | 12.5 |
| Cash From Financing Activities | 279.2 | 252.6 | 118.5 | 41.7 | 42.7 | 12.5 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 332.2 | 35.6 | (15.8) | 12.1 | 20.0 | 5.1 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | 186.1 | (101.6) | (60.0) | (29.6) | (22.6) | (7.3) |